<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2009-583</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-721</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Реологические свойства крови при псориатическом артрите: связь с воспалением и кардиоваскулярным риском</article-title><trans-title-group xml:lang="en"><trans-title>Rheological blood properties in psoriatic arthritis: relationship with inflammation and cardiovascular risk</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коротаева</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Korotaeva</surname><given-names>T V</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Loginova</surname><given-names>E Y</given-names></name><name name-style="western" xml:lang="en"><surname>Loginova</surname><given-names>E Y</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>D S</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Esakova</surname><given-names>K V</given-names></name><name name-style="western" xml:lang="en"><surname>Esakova</surname><given-names>K V</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Klimova</surname><given-names>N V</given-names></name><name name-style="western" xml:lang="en"><surname>Klimova</surname><given-names>N V</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новиков</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikov</surname><given-names>A A</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Alexandrova</surname><given-names>E N</given-names></name><name name-style="western" xml:lang="en"><surname>Alexandrova</surname><given-names>E N</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Евгений Львович</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E L</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Firsov</surname><given-names>N N</given-names></name><name name-style="western" xml:lang="en"><surname>Firsov</surname><given-names>N N</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>15</day><month>10</month><year>2009</year></pub-date><volume>47</volume><issue>5</issue><issue-title>№5 (2009)</issue-title><fpage>13</fpage><lpage>17</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Коротаева Т.В., Loginova E.Y., Новикова Д.С., Esakova K.V., Klimova N.V., Новиков А.А., Alexandrova E.N., Насонов Е.Л., Firsov N.N., 2009</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="ru">Коротаева Т.В., Loginova E.Y., Новикова Д.С., Esakova K.V., Klimova N.V., Новиков А.А., Alexandrova E.N., Насонов Е.Л., Firsov N.N.</copyright-holder><copyright-holder xml:lang="en">Korotaeva T.V., Loginova E.Y., Novikova D.S., Esakova K.V., Klimova N.V., Novikov A.A., Alexandrova E.N., Nasonov E.L., Firsov N.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/721">https://rsp.mediar-press.net/rsp/article/view/721</self-uri><abstract><p>Цель. Изучить возможность использования реологических характеристик крови в качестве показателей воспаления и кардиоваскаулярного риска (КВР) у больных псориатическим артритом (ПсА). Материал и методы. У 130 больных (51 муж. и 79 жен.) ПсА, ср. возраст – 43 года(от 39 до 48 лет), длительность ПсА – 7 лет (от 2 мес. до 42 лет), псориаза (ПС) –15 лет (от 5,5 до 26 лет), без клинических признаков ишемической болезни сердца и инсульта, в эритроагрегометре методом регистрации интенсивности обратного светорассеяния от образца крови измеряли основные показатели агрегации эритроцитов (АЭ): Кt (с-1) – общая скорость образования агрегатов эритроцитов; 13(с) – время образования линейных агрегатов эритроцитов; I2,5 [%] – параметр,характеризующий прочность самых крупных агрегатов эритроцитов; β (с-1) – гидродинамическая прочность агрегатов эритроцитов); определяли активность ПсА по индексу DAS; на основании традиционных факторов (ТФ) КВР (возраст, уровень общего холестерина (ОХС) и липопротеидов высокой плотности (ХС ЛПВП), систолическое артериальное давление (САД), наличие сахарного диабета, курение) рассчитывали относительный риск развития ИБС (баллы). В сыворотке и плазме крови определяли концентрацию С-реактивного белка (СРБ) и фибриногена стандартными методами. Корреляционный анализ проводили с использованием рангового коэффициента корреляции Спирмена (R), для сравнения групп применяли критерий Манн-Уитни (U), статистически значимым уровнем считали p&lt;0,05. Результаты. У всех больных ПсА обнаружены нарушения АЭ, соответствующие 2 степени тяжести. Выявлены значимые корреляции между параметрами АЭ [TKt, I2,,5 [β] и DAS(R=-0,32/0,32/0,33/0,25, р&lt;0,001), а также значимые корреляции всех показателей АЭ [T , Kt, I2,5, [β] с лабораторными маркерами воспаления: CPБ1 а(R= -0,37/0,41/0,46/0,32), СОЭ (R=-0,34/0,35/0,42/0,26) и наиболее сильные – с фибриногеном (R=-0,55/0,55/0,49/0,32). У всех обследованных установлены значимые корреляции большинства показателей АЭ, фибриногена с уровнем КВР: (R=-0,31/0,35/0,23/0,22, р&lt;0,001). У женщин связь между параметрами АЭ, фибриногеном и уровнем КВР оказалась сильнее: (R=-0,42/0,41/0,40/0,27). У мужчин корреляций между показателями АЭ, фибриногеном и КВР не найдено. Выводы: При ПсА показатели АЭ могут служить маркерами воспаления и КВР.</p></abstract><trans-abstract xml:lang="en"><p>Objective. To study possibility of using blood rheological parameters as markers of inflammation and cardiovascular risk (CVR) in pts with psoriatic arthritis (PA). Material and methods. 130 pts (51 male and 79 female) with PA aged from 39 to 48 years (mean age 43 years) without clinical signs of coronary heart disease (CHD) and stroke were included. Duration of PA varied from 2 months to 42 years (mean 7 years), duration of psoriasis (PS) – from 5,5 to 26 years (mean 15 years). Main measures of erythrocyte aggregation (EA) including Kt (c-1) – total speed of erythrocytes aggregates formation, T (c) – time of linear erythrocytes aggregates formation, I2,5 [%] – parameter characterizing durability of most large erythrocytes aggregates, β (c-1) – hydrodynamic durability of erythrocytes aggregates were evaluated in erythroaggregometer by registration of intensity of inverse light scattering from blood sample. PA activity was measured with DAS4. CHD development risk score was determined considering traditional CVR factors – age, total cholesterol (TCH) and high density lipoproteins (HDLP) level, systolic blood pressure (SBP), presence of diabetes, smoking. Serum C-reactive protein (CRP) and fibrinogen concentration was measured with standard methods. Correlation analysis was performed with Spearman range correlation coefficient (R), Mann-Whitney (U) test was used for groups comparison and p&lt;0,05 was considered as statistically significant level. Results. EA disturbances corresponding to 2nd stage of severity were present in all pts with PA. Significant correlation between EA parameters (T , Kt, I2,5, β) and DAS4 (R=-0,32/0,32/0,33/0,25, p&lt;0,001) as well as significant correlation of all EA parameters (T , Kt, I2,5, β) with laboratory inflammation markers: CRP (R=-0,37/0,41/0,46/0,32), ESR (R=-0,34/0,35/0,42/0,26) and most strong – with fibrinogen (R=-0,55/0,55/0,49/0,32) were revealed. Significant correlations of all EA parameters and fibrinogen with CVR level was found in all pts (R=-0,31/0,35/0,23/0,22, p&lt;0,001). In women relationship between EA parameters, fibrinogen and CVR level was stronger (R=-0,42/0,41/0,40/0,27). In men correlation between EA parameters, fibrinogen and CVR was not found. Conclusion. EA parameters in PA are biomarkers of inflammation and CVR.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>псориатический артрит</kwd><kwd>агрегация эритроцитов</kwd><kwd>воспаление</kwd><kwd>кардиоваскулярный риск</kwd></kwd-group><kwd-group xml:lang="en"><kwd>psoriatic arthritis</kwd><kwd>erythrocytes aggregation</kwd><kwd>inflammation</kwd><kwd>cardiovascular risk</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;div&gt;&lt;p&gt;Григорьянц Р. А., Фирсов Н. Н., Гасилин В. С. Реологические свойства крови у больных ишемической болезнью сердца. Кардиология 1978, 3, 11-8.&lt;/p&gt;&lt;p&gt;Firsov N. N., Bjelle A., Korotaeva T. V. et al. Clinical application of measurement of spontaneous erythrocyte aggregation and dissaggregation. Clin. Hemorheol. Microcirc., 1998, 18, 87-97.&lt;/p&gt;&lt;p&gt;Forcony S. Hemorheological disturbances and the possibility of their correction in cerebrovascular diseases. Biorheol., 1999, 36 (1-2), 77-8.&lt;/p&gt;&lt;p&gt;Gladman D., Helliwell P., Mease P. et al. Assesment of patients with Psoriatic Arthritis. Arthritis Rheum., 2004, 50(1), 24-35.&lt;/p&gt;&lt;p&gt;Gladman D., Miriam A., Li Su. et al. Cardiovascular morbidity in psoriatic arthritis (PsA), Ann. Rheum. Dis., 2008, August 12 (Pub.Online).&lt;/p&gt;&lt;p&gt;Gladman D. Psoriatic arthritis. Rheum. Dis. Clin. North. Am., 1998, 24, 829-44.&lt;/p&gt;&lt;p&gt;Grundy S. M., Pasternak R., Greenland Ph. et al. Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations. Circulation, 1999, 100, 1481-92.&lt;/p&gt;&lt;p&gt;Jones S. M., Harris C. P., Lloyd J. et al. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann. Rheum. Dis., 2000, 59, 904-9.&lt;/p&gt;&lt;p&gt;Kimhi O., Caspi D., Bornstein N. et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin. Arthritis Rheum., 2007, 57, 287-93&lt;/p&gt;&lt;p&gt;Korotaeva T. V., Firsov N. N., Bjelle A. et al. Erythrocytes aggregation in healthy donors at native and standart hematocrit: The influence of sex, age, immunoglobulins and fibrinogen concentrations. Clin. Hemorheol. Microcirc., 2007, 36 (4), 335-43.&lt;/p&gt;&lt;p&gt;Reinhart W. H. Fibrinogen – marker or mediator of vascular disease? Vasc. Med., 2003, 8(3), 211-6.&lt;/p&gt;&lt;p&gt;Rotstein R., Landau T., Twig A. et al. The erythrocyte adhesiveness/aggregation test (EAAT). A new biomarker to reveal the presence of low grade subclinical smoldering inflammation in individuals with atherosclerotic risk factors. Atherosclerosis, 2002, 165(2), 343-51.&lt;/p&gt;&lt;p&gt;Ruhenstroth-Bauer G., Porz P., Boss N. et al. The erythrocyte aggregation value as a measure of the risk of myocardial infarction and arteriosclerosis of peripheral arteries. Clin. Cardiol., 1985, 10(8), 529-34.&lt;/p&gt;&lt;p&gt;Sargento L., Sobral do Rosario H., Saldnha C. et al. Hemorheological abnormalitics in cardac failure. Biorheol., 1999, 1-2(36), 139.&lt;/p&gt;&lt;p&gt;Taylor W., Gladman D., Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum., 2006, 54, 2665–73.&lt;/p&gt;&lt;p&gt;Zeltser D., Rogowski O., Berliner S. et al. Sex differences in the expression of haemorheological determinants in individuals with atherothrombotic risk factors and in apppparently healthy people. Heart, 2004,90, 277-81&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation><mixed-citation xml:lang="en">&lt;div&gt;&lt;p&gt;Григорьянц Р. А., Фирсов Н. Н., Гасилин В. С. Реологические свойства крови у больных ишемической болезнью сердца. Кардиология 1978, 3, 11-8.&lt;/p&gt;&lt;p&gt;Firsov N. N., Bjelle A., Korotaeva T. V. et al. Clinical application of measurement of spontaneous erythrocyte aggregation and dissaggregation. Clin. Hemorheol. Microcirc., 1998, 18, 87-97.&lt;/p&gt;&lt;p&gt;Forcony S. Hemorheological disturbances and the possibility of their correction in cerebrovascular diseases. Biorheol., 1999, 36 (1-2), 77-8.&lt;/p&gt;&lt;p&gt;Gladman D., Helliwell P., Mease P. et al. Assesment of patients with Psoriatic Arthritis. Arthritis Rheum., 2004, 50(1), 24-35.&lt;/p&gt;&lt;p&gt;Gladman D., Miriam A., Li Su. et al. Cardiovascular morbidity in psoriatic arthritis (PsA), Ann. Rheum. Dis., 2008, August 12 (Pub.Online).&lt;/p&gt;&lt;p&gt;Gladman D. Psoriatic arthritis. Rheum. Dis. Clin. North. Am., 1998, 24, 829-44.&lt;/p&gt;&lt;p&gt;Grundy S. M., Pasternak R., Greenland Ph. et al. Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations. Circulation, 1999, 100, 1481-92.&lt;/p&gt;&lt;p&gt;Jones S. M., Harris C. P., Lloyd J. et al. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann. Rheum. Dis., 2000, 59, 904-9.&lt;/p&gt;&lt;p&gt;Kimhi O., Caspi D., Bornstein N. et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin. Arthritis Rheum., 2007, 57, 287-93&lt;/p&gt;&lt;p&gt;Korotaeva T. V., Firsov N. N., Bjelle A. et al. Erythrocytes aggregation in healthy donors at native and standart hematocrit: The influence of sex, age, immunoglobulins and fibrinogen concentrations. Clin. Hemorheol. Microcirc., 2007, 36 (4), 335-43.&lt;/p&gt;&lt;p&gt;Reinhart W. H. Fibrinogen – marker or mediator of vascular disease? Vasc. Med., 2003, 8(3), 211-6.&lt;/p&gt;&lt;p&gt;Rotstein R., Landau T., Twig A. et al. The erythrocyte adhesiveness/aggregation test (EAAT). A new biomarker to reveal the presence of low grade subclinical smoldering inflammation in individuals with atherosclerotic risk factors. Atherosclerosis, 2002, 165(2), 343-51.&lt;/p&gt;&lt;p&gt;Ruhenstroth-Bauer G., Porz P., Boss N. et al. The erythrocyte aggregation value as a measure of the risk of myocardial infarction and arteriosclerosis of peripheral arteries. Clin. Cardiol., 1985, 10(8), 529-34.&lt;/p&gt;&lt;p&gt;Sargento L., Sobral do Rosario H., Saldnha C. et al. Hemorheological abnormalitics in cardac failure. Biorheol., 1999, 1-2(36), 139.&lt;/p&gt;&lt;p&gt;Taylor W., Gladman D., Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum., 2006, 54, 2665–73.&lt;/p&gt;&lt;p&gt;Zeltser D., Rogowski O., Berliner S. et al. Sex differences in the expression of haemorheological determinants in individuals with atherothrombotic risk factors and in apppparently healthy people. Heart, 2004,90, 277-81&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
